Elsevier

Theriogenology

Volume 82, Issue 1, 1 July 2014, Pages 152-159
Theriogenology

Research article
Melphalan, alone or conjugated to an FSH-β peptide, kills murine testicular cells in vitro and transiently suppresses murine spermatogenesis in vivo

https://doi.org/10.1016/j.theriogenology.2014.03.014Get rights and content

Abstract

New approaches to sterilizing male animals are needed to control captive and wild animal populations. We sought to develop a nonsurgical method of permanent sterilization for male animals by administering the gonadotoxicant melphalan conjugated to peptides derived from the β-chain of FSHβ. We hypothesized that conjugating melphalan to FSHβ peptides would magnify the gonadotoxic effects of melphalan while minimizing systemic toxicity. The ability of conjugates of melphalan and FSHβ peptides to kill murine testicular cells was first tested in vitro in a three-dimensional testicular cell coculture system. In this system, melphalan caused considerable cell death as measured both by increases in lactate dehydrogenase concentrations in the culture supernatant and direct visualization of the cultures. Of the conjugates tested, melphalan conjugated to a 20-amino acid peptide derived from human FSHβ consisting of amino acids 33 to 53 (FSHβ (33–53)-melphalan) was very potent, with cell cytotoxicity and lactate dehydrogenase release roughly one-half that of melphalan. The effects of melphalan and FSHβ (33–53)-melphalan on spermatogenesis were then tested in vivo in mature C56Bl/6 male mice. Four weeks after intraperitoneal injection, all mice treated with either FSHβ (33–53)-melphalan or melphalan had approximately 75% reductions in testicular spermatid counts compared with control animals. Testicular histology revealed significant reduction in mature spermatids and spermatocytes in most tubules. However, 12 weeks after the injection, testicular spermatid counts and histology were similar to controls, except in one animal receiving FSHβ (33–53)-melphalan that had no apparent spermatogenesis. We conclude that melphalan and FSHβ (33–53)-melphalan are potent gonadotoxicants in male mice resulting in marked suppression of spermatogenesis 4 weeks after a single intraperitoneal injection. However, this effect is transient in most mice as spermatogenesis is similar to control animals 12 weeks after drug administration. Melphalan or FSHβ (33–53)-melphalan may be useful for the temporary control of fertility in male animals, but additional research will be needed to develop a single dose method of permanent sterilization for male animals.

Introduction

The most common method of sterilizing male animals relies on removal of the testes, which requires skilled personnel and can cause significant postprocedural pain [1]. Removal of the testes also deprives the animal of testosterone, which may lead to health and behavioral problems [2], and increase the risk of prostate cancer [3], [4], [5] or osteoporosis [2], [6] later in life. An alternative approach to male sterilization is the injection of a solution of calcium chloride [7] or zinc gluconate [8] directly into the testes. These injections are very effective from a contraceptive standpoint; however, severe injection site reactions requiring surgery can occur in up to 4% of recipients [9], with others experiencing scrotal ulceration or dermatitis [10]. Therefore, there is a need for novel methods of permanent sterilization for male animals. Ideally, such a method would be inexpensive and administered with a single injection.

Several investigators have examined the potential of gonadotoxicants for the purposes of male sterilization. For example, ketoconazole [11], alpha-chlorohydrin [12], and emblein [13] have been tested in animals. However, the suppression of spermatogenesis was incomplete, and systemic toxicity was limited [14]. We sought to test a novel approach to male sterilization using the potent gonadotoxicant melphalan. Melphalan, an alkylating agent, is widely used in the treatment of lymphomas and multiple myeloma in both humans and animals. Infertility is frequently seen after administration of melphalan [15], [16], and melphalan is fairly unique among gonadotoxicants in that it kills both spermatogonial stem cells and dividing germ cells in vivo [17]. Melphalan has been used extensively in animals for the treatment of malignancies [18], [19], and its pharmacokinetics and marrow toxicity are well described [20], [21]. Despite its widespread use in animals, the effect of melphalan on spermatogenesis in animals has not been well studied. We sought to: (1) determine if melphalan could be used to induce sterility, and (2) investigate if we could facilitate melphalan effect and minimize any toxicity by targeting the melphalan specifically to the testes via conjugation to peptides derived from the β-chain of human FSH-β.

FSH is a protein hormone produced in the anterior pituitary. FSH binds to the FSH receptor (FSHr) on Sertoli cells within the seminiferous tubules of the testes [22], stimulating them to nurture the developing germ cells. The FSHα chain is not required for binding to the FSHr, but the FSHβ chain specifically binds to the FSHr with high affinity and is required for receptor activation [23]. Because of its high expression in the gonads and very low levels of expression in other tissues, FSHr provides an elegant targeting mechanism for drug delivery to the gonads. Indeed, FSHβ has been shown to be an effective gonad-specific drug delivery vehicle for experimental forms of reversible contraception in mice. In one such study, the contraceptive efficacy of adjudin was increased 10,000-fold by conjugation to FSHβ [24]. In another example, FSHβ conjugated to a peptide that interrupted the integrity of the blood–testes barrier caused significant loss of germ cells and a decrease in fertility [25].

Use of the entire FSHβ molecule for targeting, however, is impractical for widespread use because of the expense of either the chemical synthesis or recombinant production of the entire FSHβ chain, which is 112 amino acids in length. Fortunately, FSHβ-derived peptides that bind to the FSHr with high affinity have been described [26], [27], [28], [29], [30]. The most attractive candidates for drug delivery are peptides based on the amino acids in positions 33 to 53 and 81 to 95 of FSHβ [27], [28]. Each of these peptides sequences has good in vitro FSHreceptor-binding inhibition and demonstrated in vivo efficacy. Furthermore, there is good recognition of these conserved peptides by the FSHr across species [27], [31]. Peptides with terminal modifications and substitutions of serine for cysteine increase FSHr binding, as measured by competitive inhibition studies [26], [30]. These peptides have been used to target drugs to the gonadal tissue. Both peptides specifically targeted ovarian cancer cells with nanoparticles [32], [33]. Therefore, we hypothesized that the conjugation of FSHβ-derived peptides to the gonadotoxicant melphalan would allow for sterilization of male animals while minimizing the side effects induced by high-dose melphalan administered alone. We tested melphalan and FSHβ-melphalan conjugates in vitro and in vivo for their ability to kill mouse testicular cells and thereby induce sterility.

Section snippets

Melphalan and FSHβ-melphalan conjugate preparation

Melphalan was obtained commercially (Sigma, St. Louis, MO, USA). Two different FSHβ-derived peptide sequence residues β33 to 53 and β81 to 95 were employed as the carriers for melphalan. The melphalan was conjugated to either the amino or carboxy terminus of each peptide, with or without the presence of terminal modifications and addition or deletion of terminal amino acids. The molecular weights and FSHβ-amino acid composition of the 16 conjugates tested are listed in Table 1. FSHβ-melphalan

In vitro cytotoxicity testing of melphalan and FSHβ-melphalan conjugates

The results of the cytotoxicity testing of melphalan and the FSHβ-melphalan conjugates (Table 1), as demonstrated by the release of LDH over time, are summarized in Figure 1. Good cytotoxicity was observed when the N-terminal acetate was included with the β33 to 53 peptide C-terminal conjugate F. The β33 to 53 peptide lacking an N-terminal acetate was less effective (C, D) than conjugate F. There was also less cytotoxicity when the melphalan was placed on the N-terminus of the β33 to 53 peptide

Discussion

Herein, we report on our efforts to develop a method of permanently sterilizing male animals by the use of a gonadotoxicant, melphalan, alone and conjugated to a peptide derived from FSHβ intended to specifically target the melphalan to the testes. Our extensive in vitro work resulted in the identification of a conjugate consisting of a 20-amino acid peptide and melphalan (conjugate F) that exhibited significant cytotoxicity in vitro that appeared to be more specific for testicular cells as

Acknowledgments

The authors would like to thank Erin Pagel MA for assistance with the sperm analysis and David W. Amory MD, PhD for thoughtful review of the article. This work was funded by the University of Washington Royalty Research Fund, and in part, by the Eunice Kennedy Shriver National Institute of Child Health and Human Development through cooperative agreement U54 HD-42454 as part of the Cooperative Contraceptive Research Centers Program and funds from Focused Scientific, Inc. as well as Grants 1 U01

References (44)

  • M. Tagirov et al.

    The effect of busulfan treatment on endogenous spermatogonial stem cells in immature roosters

    Poult Sci

    (2012)
  • M. Katzler et al.

    Non-surgical methods of contraception and sterilization

    Theriogenology

    (2006)
  • K.R. Salmeri et al.

    Gonadectomy in immature dogs: effects on skeletal, physical and behavioral development

    J Am Vet Med Assoc

    (1991)
  • F.W. Bell et al.

    Clinical and pathologic features of prostatic adenocarcinoma in sexually intact and castrated dogs: 31 cases (1970-1987)

    J Am Vet Med Assoc

    (1991)
  • J. Obradovich et al.

    The influence of castration on the development of prostatic carcinoma in the dog, 43 cases (1978-1985)

    J Vet Intern Med

    (1987)
  • S. Fukuda et al.

    Effects of orchidectomy on bone metabolism in beagle dogs

    J Vet Med Sci

    (2000)
  • E.C. Oliverira et al.

    Intratesticular injection of a zinc-based solution as a contraceptive for dogs

    Theriogenology

    (2007)
  • J.K. Levy et al.

    Comparison of intratesticular injection of zinc gluconate versus surgical castration to sterilize male dogs

    Am J Vet Res

    (2008)
  • V. Tepsumethanaon et al.

    Intratesticular injection of a balanced zinc solution for permanent sterilization of dogs

    J Med Assoc Thai

    (2005)
  • B.H. Vickery et al.

    Orally administered ketoconazole rapidly appears in seminal plasma and suppresses sperm motility

    Adv Contracept

    (1985)
  • V.P. Dixit et al.

    Reversible changes in the testes and epididymides of dogs treated with alpha-chlorohydrin

    Acta Biol Med Ger

    (1975)
  • V.P. Dixit et al.

    Reversible contraception like activity of embelin in male dogs (Canis indicus Linn)

    Andrologia

    (1983)
  • Cited by (10)

    • Juvenile exposure and adult risk assessment with single versus repeated exposure of melphalan in the germ cells of male SD rat: Deciphering the molecular mechanisms

      2022, Reproductive Toxicology
      Citation Excerpt :

      Melphalan acts as a potent genotoxic agent as evident by chromosomal aberrations and micronuclei formation in rodent bone marrow and peripheral blood cells even at low doses [20,21]. It kills both spermatogonial stem cells and the dividing germ cells in vivo and therefore, might be a potent risk factor for male fertility in children who have undergone melphalan treatment [22]. Moreover, it has been identified as a second chemical after chlorambucil for which specific locus mutation in the early spermatids of the mouse has been reported [23].

    • Melphalan: Recent insights on synthetic, analytical and medicinal aspects

      2022, European Journal of Medicinal Chemistry
      Citation Excerpt :

      In another study, Amory et al., prepared peptide conjugate of melphalan and FSHβ that showed potent in vitro cytotoxic activity. In vivo study showed 75% reduction in spermatogenesis as compared to control sample [83]. Dipeptide derivative of melphalan i.e. (L-melphalanyl-p-l-fluorophenylalanine ethyl ester), which was later termed as melflufen, considered an intermediate between melphalan and P2 (L-prolyl-m-L-sarcolysylp-l-fluorophenylalanine ethyl ester) [84].

    View all citing articles on Scopus
    View full text